"I suggest that the state should give policy guidance and support to the pharmaceutical and other intermediate industries, build a high-end pharmaceutical industry chain, and improve the level of the source green and intrinsically safe intermediate industry." National Committee of the Chinese People's Political Consultative Conference, Nanjing University President Qiao Xu said.

Qiao Xu pointed out that at present, the structural imbalance of China's pharmaceutical and other intermediates industry chain is manifested in the convergence of product structure, single variety, overcapacity in most of them, and insufficient supply of medium and high-end products. Among them, the sales of pharmaceuticals and their intermediates are highly dependent on global orders, mainly concentrated in low value-added bulk products such as vitamin C and penicillin, while higher-end pharmaceutical intermediates, specialty APIs and patented APIs often rely on imports.

"Due to the rising cost of enterprise investment in environmental protection devices, capacity constraints, a number of enterprises are difficult to save themselves, resulting in the pharmaceutical and other intermediates industry into a 'one-size-fits-all' or 'one-cut' dilemma, but in the new situation of the normalization of the prevention and control of the new coronary pneumonia epidemic, prevention and control materials and vaccine drug development and production, such as the urgent need for pharmaceutical and other chemical intermediates and other material support." Qiao Xu said.

"Pharmaceutical and other intermediate industries have become an important direction for countries to develop fine chemicals because they can not only avoid patent barriers, but also have the advantages of high investment profit margin and added value." Qiao Xu said that with the rise of anti-globalization and protectionism, and the increasing risk of foreign technology blockade and decoupling, the risk of chain breakage in the global chemical and pharmaceutical industry chain is also increasing.

He said that in order to cope with the test of possible chain breakage in pharmaceutical and other industries, we can start from three aspects:

To tap the potential inward and build an "internal cycle" industrial chain. Accelerate the promotion of domestic independent and controllable substitution plan, and promote the overall upgrading of the integrated internal cycle industry chain of "pharmaceutical intermediates, raw materials and preparations. Relevant industries should extend the industrial chain upstream and downstream, that is, closely docking with the production of basic chemical raw materials to avoid the monopoly of overseas key raw materials; at the same time, strengthen the end products such as raw materials and pharmaceutical preparations, customize the production of intermediates such as pharmaceuticals, and keep the high-end manufacturing industry of the value chain in China.

Strengthen innovation and consolidate the technical support system. Pay attention to scientific research investment, establish various engineering technology centers with interdisciplinary and high starting point, and provide carriers for the research and development of new varieties and new processes of intermediates such as medicine. Focus on the prevention and prevention needs of major infectious diseases and respiratory diseases, aim at high-end drugs and their intermediates, encourage the inflow of talents and capital, adopt biotechnology and advanced green technology, improve the utilization rate of raw materials for the production of pharmaceuticals and their intermediates, reduce pollutant emissions, and create a green process with low pollution, low energy consumption and high added value.

Strengthen clusters and create a "symbiotic system" of division of labor and cooperation and mutual benefit ". Encourage technology-based enterprises with strong strength to stand out, strengthen the integration of production factors and business process reengineering, and improve the level of industrial foundation and industry concentration. Encourage small and medium-sized enterprises to give full play to their advantages of being close to the market, making rapid decisions, and flexible mechanisms, take differentiated product routes, and cultivate a group of "invisible kings" with high levels of specialization and strong technological competitiveness ".